|
|
Crédit Agricole Private Equity is an AMF-accredited asset management subsidiary of Crédit Agricole S.A., specializing in private equity investment. A team of 40 professionals manage €1.5 billion through venture and innovation funds. Crédit Agricole Private Equity provides advice and support for business managers implementing growth plans. For additional information on Crédit Agricole Private Equity click here |
|
|
Forbion Capital Partners (formerly ABN AMRO Capital Life Sciences) invests in Life Sciences and Biomedical Technology companies developing world-class drugs and technologies, with a clear focus on product development. For additional information on Forbion Capital Partners click here |
|
|
Giza Venture Capital, established in 1992, is a pioneer investor in early-stage technology companies. Giza currently manages four funds totaling $500 million. Giza has investment professionals with a wealth of expertise and experience in Communication, Information Technology, Internet and Life Sciences. For additional information on Giza Venture Capital click here |
|
|
Oxford Bioscience Partners (OBP) is a life science venture capital firm that provides equity financing and management assistance to start-up and early-stage, entrepreneurial-driven companies in the bioscience and healthcare industries. The General Partners of OBP currently manage venture funds with committed capital of more than $800 million. For additional information on Oxford Bioscience Partners click here |
|
|
Foundation Medical Partners is a national, independent venture capital investment firm focused exclusively on healthcare opportunities. The firm has a special interest in medical devices that demonstrate the capability to improve the practice of medicine and human health. For additional information on Foundation Medical Partners click here |
|
|
SB Life Science Ventures is a venture capital fund with committed capital of about $100 million and is the only life sciences venture capital fund backed by prominent institutional investors from Japan. The firm aims to identify and invest in exceptional businesses that have the potential to transform the practice of medicine and healthcare. For additional information on SB Life Science Ventures click here |